Explore evidence

75 %Viral suppression in the ART 12-24 group was 75.0% in urban sites.

CamerounVIH/sidapublished 2018EClinicalMedicineeurope_pmcdocument of 6 observations

4.1 %In Yaoundé, the capital city of Cameroon, the prevalence of WHO-defined transmitted HIV-1 drug resistance mutations (DRMs) among ART-naive individuals was 4.1% in 2002.

CamerounVIH/sidaobserved 2002published 2011AIDS (London, England)europe_pmcdocument of 5 observationsDOI 10.1097/qad.0b013e32834bbbe9

5 peptidesThe median number of peptides recognized per individual was 5.

CamerounVIH/sidapublished 2009RetrovirologyOpenAlexdocument of 6 observationsDOI 10.1186/1742-4690-6-s3-p273

7 %12-month adolescent loss to follow-up increased in the first 3 years of the programme, peaking at 7%, subsequently falling to below 5% by the end of the study period.

CamerounVIH/sidapublished 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

21 %Among 169 HIV-1-infected patients in Cameroon, 21% were coinfected with hepatitis B virus (HBV) or hepatitis C virus (HCV).

Camerounhépatite B · hépatite C · VIH/sidapublished 2010BMC Public HealthOpenAlexdocument of 6 observationsDOI 10.1186/1471-2458-10-105

10 %Phylogenetic analysis of the gp41 region of 123 HIV-1-seropositive specimens from Cameroon showed that 12 (10%) were subtype D.

CamerounVIH/sidapublished 2000AIDS Research and Human RetrovirusesOpenAlexdocument of 7 observations

39.5 yearsThe mean age of the recruited HIV-infected Cameroonians was 39.5 years.

CamerounVIH/sidapublished 2013Diabetes & metabolismeurope_pmcdocument of 12 observations

11 %Among HIV-1 protease (PR) sequences from drug-naïve Cameroonians, the secondary PI resistance-associated mutations 10I or 10V were present in 11% of strains.

CamerounVIH/sidapublished 2002Journal of Clinical MicrobiologyOpenAlexdocument of 12 observations

15.9 %Pretreatment HIV drug resistance (PDR) frequency among all antiretroviral therapy initiators was 15.9% overall.

CamerounVIH/sidapublished 2018Journal of Antimicrobial ChemotherapyOpenAlexdocument of 9 observationsDOI 10.1093/jac/dky443

2 foldThe risk of hepatotoxicity was 2-fold higher in coinfected patients compared to monoinfected patients.

Camerounhépatite B · hépatite C · VIH/sidapublished 2010BMC Public HealthOpenAlexdocument of 6 observationsDOI 10.1186/1471-2458-10-105

43.6 %The R211K accessory mutation associated with NRTI resistance was observed in 43.6% of the 142 HIV-1 samples.

CamerounVIH/sidapublished 2000Journal of Clinical MicrobiologyOpenAlexdocument of 19 observations

26 %The L10I/V mutation was identified in 26% of the 142 HIV-1 isolates in the protease gene.

CamerounVIH/sidapublished 2000Journal of Clinical MicrobiologyOpenAlexdocument of 19 observations

5.3 %Pretreatment HIV drug resistance (PDR) prevalence among ART initiators with no prior exposure to antiretrovirals in rural areas of Cameroon was 5.3% (95% CI 1.4%–17.5%).

CamerounVIH/sidaobserved 2015published 2018The Journal of antimicrobial chemotherapyeurope_pmcdocument of 12 observationsDOI 10.1093/jac/dky221

52 %Fifty-two percent of the recruited HIV-infected Cameroonians were using a stavudine-containing regimen.

CamerounVIH/sidapublished 2013Diabetes & metabolismeurope_pmcdocument of 12 observations

90 %In 2010, 90% of 40 ART sites in Cameroon attained the target for good ARV prescribing practices (target = 100%).

CamerounVIH/sidaobserved 2010published 2012PLoS ONEOpenAlexdocument of 5 observationsDOI 10.1371/journal.pone.0036777

3.3 log10_copies_per_mlPlasma viral load declined by a median of 3.3 log10 copies/ml at 12 months.

CamerounVIH/sidaobserved 12 monthspublished 2005Antiviral TherapyOpenAlexdocument of 8 observationsDOI 10.1177/135965350501000208

9.2 %At endpoint, 9.2% of 141 HIV-infected adult patients died.

CamerounVIH/sidaobserved 2009-2011published 2013PLoS ONEOpenAlexdocument of 8 observationsDOI 10.1371/journal.pone.0072680

-0.32 SMDHIV infection was associated with lower body mass index with a standardized mean difference of -0.32.

Camerounbody mass index · VIH/sidapublished 2013International journal of epidemiologyeurope_pmcdocument of 10 observationsDOI 10.1093/ije/dyt198

14.2 %Pretreatment HIV drug resistance (PDR) prevalence among ART initiators in urban areas of Cameroon was 14.2% (95% CI 6.6%–27.9%).

CamerounVIH/sidaobserved 2015published 2018The Journal of antimicrobial chemotherapyeurope_pmcdocument of 12 observationsDOI 10.1093/jac/dky221

50 %Over half of HIV+ persons attending a health campaign had undetectable HIV RNA one year after implementing intensified community-based HIV testing and linkage.

CamerounVIH/sidapublished 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

9 %The combination of all assays generated up to 9% of samples with indeterminate HIV status.

CamerounVIH/sidapublished 2009PLoS ONEOpenAlexdocument of 3 observationsDOI 10.1371/journal.pone.0007702

20 samplesAmong 219 HIV-1-positive samples collected in different African countries, 20 (9.1%) had discordant subtypes between gag and env.

CamerounVIH/sidapublished 2000JAIDS Journal of Acquired Immune Deficiency SyndromesOpenAlexdocument of 4 observations

1.92 hazard ratioLoss to follow-up was significantly higher in adults than adolescents (HR=1.92, p<0.05).

CamerounVIH/sidapublished 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

67.7 %Viral suppression in the ART 12-24 group was 67.7% in rural sites.

CamerounVIH/sidapublished 2018EClinicalMedicineOpenAlexdocument of 3 observationsDOI 10.1016/j.eclinm.2018.06.005

10.4 %10.4% of HIV-1 genomes detected were heretofore undescribed unique recombinant forms (URF) present in only a single person.

CamerounVIH/sidapublished 2010RetrovirologyOpenAlexdocument of 3 observationsDOI 10.1186/1742-4690-7-39